First Author: J.Chhablani INDIA
Co Author(s): M. Eldeeb E. Chan C. Dedhia A. Mansour
Back to previous
To report the 12-month efficacy and safety outcomes of intravitreal ziv-aflibercept in macular edema secondary to central retinal vein occlusion (CRVO).
Interventional case series documenting 12-month outcomes of intravitreal ziv-aflibercept in 6 patients with treatment-naive macular edema secondary to CRVO. All patients had comprehensive ophthalmic examination, spectral domain optical coherence tomography at baseline and all follow-up visits, and fluorescein angiography was performed. Retreatment decisions were based on recurrence or persistence of intraretinal or subretinal fluid, deterioration in visual acuity (VA), increase in central subfield thickness (CST) by ≥50 μm from the previous visit, or lowest recorded CST.
All participants were Middle-Eastern (2 males, 4 females), with a mean age of 53.5 years. From baseline to 12 months, the mean LogMAR VA improved from 0.86 (Snellen ≈ 20/145) to 0.33 (Snellen ≈ 20/40), and central macular thickness decreased from 519 μm to 255 μm. No eyes had uveitis, cataract progression, intraocular pressure (IOP) or elevations, or systemic adverse events.
Ziv-aflibercept achieves favorable intermediate-term functional and structural outcomes in macular edema secondary to CRVO. No safety concerns were raised. Low-cost ziv-aflibercept may thus be useful for CRVO in resource-poor countries. Further prospective studies in larger cohorts are needed further establish the efficacy and safety of this agent.